Drug · CHEMBL128
SUMATRIPTAN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. SUMATRIPTAN. Drugs and targets, record CHEMBL128. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL128
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 1 of its 12 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HTR1B | 5-hydroxytryptamine receptor 1B | Serotonin 1b (5-HT1b) receptor agonist | AGONIST | https://conductscience.org/library/genes/3351 |
| HTR1D | 5-hydroxytryptamine receptor 1D | Serotonin 1d (5-HT1d) receptor agonist | AGONIST | https://conductscience.org/library/genes/3352 |
Source ChEMBL
Diseases12
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 12Source Open Targets
See all 12 diseasesTrials92
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01430442 | Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine | Phase 2 | 1,026 | 2020-09-03 | sumatriptan | Its name | ClinicalTrials.gov |
| NCT00897104 | MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029) | Phase 3 | 933 | 2010-07-23 | sumatriptan | Its name | ClinicalTrials.gov |
| NCT01248468 | Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine | Phase 4 | 752 | 2012-07-30 | sumatriptan | Its name | ClinicalTrials.gov |
| NCT00387881 | TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1) | Phase 3 | 679 | 2009-07-10 | sumatriptan | Its name | ClinicalTrials.gov |
| NCT00488514 | Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents | Phase 3 | 656 | 2010-09-06 | sumatriptan | Its name | ClinicalTrials.gov |
| NCT00843024 | Migraine Study in Adolescent Patients | Phase 3 | 589 | 2011-05-09 | sumatriptan | Its name | ClinicalTrials.gov |
| NCT00724815 | The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine | Phase 3 | 530 | 2013-05-07 | sumatriptan | Its name | ClinicalTrials.gov |
| NCT00792636 | A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period | Phase 4 | 407 | 2010-11-04 | sumatriptan, sumatriptan and naproxen sodium combination | Its name | ClinicalTrials.gov |
| NCT00449787 | Comparing Naproxen to Sumatriptan for Emergency Headache Patients | Phase 4 | 401 | 2012-11-29 | sumatriptan | Its name | ClinicalTrials.gov |
| NCT00573170 | TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults | Phase 3 | 375 | 2010-12-29 | sumatriptan | Its name | ClinicalTrials.gov |
1 to 10 of 92
See all 92 trialsComparisons in its trials54
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sumatriptan/Naproxen vs Placebo: serious adverse events | 0 of 254 | 0 of 246 | 500 | NCT00387881 | Trial comparisons |
| NP101 Patch vs Placebo Patch: serious adverse events | 0 of 234 | 0 of 235 | 469 | NCT00724815 | Trial comparisons |
| NP101 Patch vs Placebo Patch: Photophobia Free at Two Hours | 116 of 226 | 83 of 228 | 454 | NCT00724815 | Trial comparisons |
| NP101 Patch vs Placebo Patch: Pain Free at Two Hours | 40 of 226 | 21 of 228 | 454 | NCT00724815 | Trial comparisons |
| NP101 Patch vs Placebo Patch: Nausea Free at Two Hours | 189 of 226 | 144 of 228 | 454 | NCT00724815 | Trial comparisons |
| NP101 Patch vs Placebo Patch: Phonophobia Free at Two Hours | 125 of 226 | 89 of 228 | 454 | NCT00724815 | Trial comparisons |
| 20 mg Sumatriptan Nasal Powder vs 100 mg Sumatriptan Tablet: serious adverse events | 0 of 219 | 0 of 228 | 447 | NCT01667679 | Trial comparisons |
| Sumatriptan/Naproxen vs Placebo: Subjects Who Used Rescue Medication From 0 - 24 Hours After Treatment | 61 of 222 | 101 of 221 | 443 | NCT00387881 | Trial comparisons |
| Sumatriptan/Naproxen vs Placebo: Sustained Headache Relief 2-24 Hours After Treatment | 110 of 222 | 77 of 221 | 443 | NCT00387881 | Trial comparisons |
| Sumatriptan-Naproxen Sodium vs Placebo: serious adverse events | 0 of 140 | 0 of 135 | 275 | NCT00383162 | Trial comparisons |
1 to 10 of 54
See all 54 comparisons in its trialsPapers from its trials53
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL128
GET https://conductscience.org/api/drugs/v1/CHEMBL128/trials?page=2